Trinity Biotech plc (TRIB) - Total Liabilities
Based on the latest financial reports, Trinity Biotech plc (TRIB) has total liabilities worth $158.43 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Trinity Biotech plc equity growth rate to track the company's year-over-year net asset growth rate.
Trinity Biotech plc - Total Liabilities Trend (1993–2024)
This chart illustrates how Trinity Biotech plc's total liabilities have evolved over time, based on quarterly financial data. See TRIB cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Trinity Biotech plc Competitors by Total Liabilities
The table below lists competitors of Trinity Biotech plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Rackla Metals Inc
V:RAK
|
Canada | CA$1.31 Million |
|
Pelikan International Corp
KLSE:5231
|
Malaysia | RM64.67 Million |
|
Bharat Road Network Limited
NSE:BRNL
|
India | Rs10.45 Billion |
|
DT&C Co. Ltd
KQ:187220
|
Korea | ₩149.75 Billion |
|
CPR Gomu Industrial PCL
BK:CPR
|
Thailand | ฿64.46 Million |
|
Genolution Inc.
KQ:225220
|
Korea | ₩26.44 Billion |
|
NEXTCHIP Co. Ltd
KQ:092600
|
Korea | ₩21.52 Billion |
|
Australian Vintage Ltd
AU:AVG
|
Australia | AU$240.19 Million |
Liability Composition Analysis (1993–2024)
This chart breaks down Trinity Biotech plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Trinity Biotech plc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.90 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Trinity Biotech plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Trinity Biotech plc (1993–2024)
The table below shows the annual total liabilities of Trinity Biotech plc from 1993 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $138.47 Million | +66.06% |
| 2023-12-31 | $83.38 Million | -11.56% |
| 2022-12-31 | $94.28 Million | -20.92% |
| 2021-12-31 | $119.21 Million | -10.11% |
| 2020-12-31 | $132.62 Million | +4.95% |
| 2019-12-31 | $126.36 Million | +17.89% |
| 2018-12-31 | $107.18 Million | -15.88% |
| 2017-12-31 | $127.42 Million | -9.55% |
| 2016-12-31 | $140.87 Million | -2.90% |
| 2015-12-31 | $145.07 Million | +216.30% |
| 2014-12-31 | $45.87 Million | +5.50% |
| 2013-12-31 | $43.48 Million | +55.12% |
| 2012-12-31 | $28.03 Million | +38.97% |
| 2011-12-31 | $20.17 Million | +2.96% |
| 2010-12-31 | $19.59 Million | -63.11% |
| 2009-12-31 | $53.10 Million | -16.51% |
| 2008-12-31 | $63.60 Million | -19.62% |
| 2007-12-31 | $79.13 Million | -3.34% |
| 2006-12-31 | $81.87 Million | +60.58% |
| 2005-12-31 | $50.98 Million | +46.97% |
| 2004-12-31 | $34.69 Million | -8.30% |
| 2003-12-31 | $37.83 Million | +43.51% |
| 2002-12-31 | $26.36 Million | +28.60% |
| 2001-12-31 | $20.50 Million | +68.18% |
| 2000-12-31 | $12.19 Million | -45.40% |
| 1999-12-31 | $22.32 Million | -26.58% |
| 1998-12-31 | $30.40 Million | +73.71% |
| 1997-12-31 | $17.50 Million | +525.00% |
| 1996-12-31 | $2.80 Million | +64.71% |
| 1995-12-31 | $1.70 Million | -5.56% |
| 1994-12-31 | $1.80 Million | 0.00% |
| 1993-12-31 | $1.80 Million | -- |
About Trinity Biotech plc
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; se… Read more